公开(公告)号：US20040185061A1

公开(公告)日：2004-09-23

申请号：US10825219

申请日：2004-04-16

申请人： Innogenetics N.V.

发明人： Alfons Bosman ,  Erik Depla ,  Geert Maertens

IPC分类号： C12Q001/70 ,  A61K039/29 ,  C07K014/02

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K16/109 ,  C12N2770/24222

摘要： The present invention relates to HCV proteins in which cysteine residues are reversibly protected during purification. Eventually, this purification procedure results in HCV proteins with biological activity and a native-like protein conformation, which present corresponding epitopes. The present invention pertains also to drug screening methods using these HCV proteins, and diagnostic and therapeutic applications, such as vaccines and drugs.

摘要翻译： 本发明涉及其中半胱氨酸残基在纯化期间被可逆保护的HCV蛋白质。 最终，该纯化程序导致具有生物活性的HCV蛋白质和呈现相应表位的天然样蛋白质构象。 本发明还涉及使用这些HCV蛋白质的药物筛选方法，以及诊断和治疗应用，例如疫苗和药物。